Exelixis

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Exelixis 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About EXEL

Exelixis, Inc. is an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. 

CEO
Michael M. Morrissey
CEOMichael M. Morrissey
Employees
1,077
Employees1,077
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
1994
Founded1994
Employees
1,077
Employees1,077

EXEL Key Statistics

Market cap
13.93B
Market cap13.93B
Price-Earnings ratio
17.88
Price-Earnings ratio17.88
Dividend yield
Dividend yield
Average volume
3.38M
Average volume3.38M
High today
$56.20
High today$56.20
Low today
$54.00
Low today$54.00
Open price
$54.43
Open price$54.43
Volume
1.31M
Volume1.31M
52 Week high
$56.20
52 Week high$56.20
52 Week low
$33.76
52 Week low$33.76

Stock Snapshot

Exelixis(EXEL) stock is priced at $54.96, giving the company a market capitalization of 13.93B. It carries a P/E multiple of 17.88.

On 2026-07-02, Exelixis(EXEL) stock moved within a range of $54.00 to $56.20. With shares now at $54.96, the stock is trading +1.8% above its intraday low and -2.2% below the session's peak.

Trading activity shows a volume of 1.31M, compared to an average daily volume of 3.38M.

The stock's 52-week range extends from a low of $33.76 to a high of $56.20.

The stock's 52-week range extends from a low of $33.76 to a high of $56.20.

EXEL News

TipRanks 7h
Exelixis price target raised to $52 from $43 at UBS

UBS analyst Ashwani Verma raised the firm’s price target on Exelixis (EXEL) to $52 from $43 and keeps a Neutral rating on the shares. The stock is resilient, bu...

Simply Wall St 6d
Is Exelixis Fully Valued On Its STELLAR 303 Trial Update?

Exelixis (EXEL) shares are in focus after the company reported final subgroup data from its phase 3 STELLAR-303 trial of zanzalintinib plus atezolizumab in meta...

Is Exelixis Fully Valued On Its STELLAR 303 Trial Update?

Analyst ratings

50%

of 20 ratings
Buy
40%
Hold
50%
Sell
10%

People also own

Based on the portfolios of people who own EXEL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.